Download Files:
Products Details
Product Description
– LY-2584702 free base is a selective ATP competitive inhibitor of p70S6K with an IC50 of 4 nM. In S6K1 enzyme assay, the IC50 of LY-2584702 is 2 nM.
Web ID
– HY-12493
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C21H19F4N7
Citations
– Harvard Medical School LINCS LIBRARY|Hepatology. 2022 Sep 21.|Immunity. 2021 Sep 14;54(9):2042-2056.e8.|Pharmacol Res. 2021 Oct 4;105871.|Theranostics. 2022 Jan 1;12(3):1204-1219.
References
– [1]Chen B, et al. Hyperphosphorylation of RPS6KB1, rather than overexpression, predicts worse prognosis in non-small cell lung cancer patients. PLoS One. 2017 Aug 9;12(8):e0182891.|[2]Phung TL, et al. Akt1 and akt3 exert opposing roles in the regulation of vascular tumor growth. Cancer Res. 2015 Jan 1;75(1):40-50.|[3]Tolcher A, et al. A phase I trial of LY2584702 tosylate, a p70 S6 kinase inhibitor, in patients with advanced solid tumors. Eur J Cancer. 2014 Mar;50(5):867-75.
CAS Number
– 1082949-67-4
Molecular Weight
– 445.42
Compound Purity
– 99.56
SMILES
– CN1C=C(C2=CC=C(F)C(C(F)(F)F)=C2)N=C1C3CCN(C4=C5C(NN=C5)=NC=N4)CC3
Clinical Information
– Phase 1
Research Area
– Cancer
Solubility
– DMSO : ≥ 4.5 mg/mL
Target
– Ribosomal S6 Kinase (RSK)
Isoform
– p70S6K
Pathway
– MAPK/ERK Pathway
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
